Page 137 - 2020年2月第31卷第3期

munoglobulin between mice and men：more than meets [35] WATKINS JM，DIMACHKIE MM，RILEY P，et al. Sub-
the eye[J]. Front Immunol，2015.DOI：10.3389/fimmu. cutaneous immunoglobulin therapy for chronic inflamma-
2015.00197. tory demyelinating polyneuropathy：a nursing perspective
[24] DOMINGUEZ-SOTO A，DE LAS CM，BRAGADO R， [J]. J Neurosci Nurs，2019，51（4）：198-203.
et al. Intravenous immunoglobulin promotes antitumor re- [36] COCITO D，PECI E，CANAVESE C，et al. Feasibility，
sponses by modulating macrophage polarization[J]. J Im- clinical and laboratory efficacy of lower volumes of subcu-
munol，2014，193（10）：5181-5189. taneous immunoglobulin administration via manual push
[25] ISSEKUTZ AC，ROWTER D，MIESCHER S，et al. Intra- technique in chronic inflammatory demyelinating polyra-
venous IgG（IVIG）and subcutaneous IgG（SCIG）prepa- diculoneuropathy patients[J]. J Peripher Nerv Syst，2019.
rations have comparable inhibitory effect on T cell activa- DOI：10.1111/jns.12312.
tion，which is not dependent on IgG sialylation，mono- [37] SALA TP，CRAVE JC，DURACINSKY M，et al. Efficacy
cytes or B cells[J]. Clin Immunol，2015，160（2）：123-132. and patient satisfaction in the use of subcutaneous immu-
[26] CORBI AL，SANCHEZ-RAMON S，DOMINGUEZ-SO- noglobulin immunotherapy for the treatment of auto-im-
TO A. The potential of intravenous immunoglobulins for mune neuromuscular diseases[J]. Autoimmun Rev，2018.
cancer therapy：a road that is worth taking?[J]. Immuno- DOI：10.1016/j.autrev.2018.03.010.
therapy，2016，8（5）：601-612. [38] DIMACHKIE M，VAN SCHAIK I，BRIL V，et al. Practi-
[27] NIMMERJAHN F，RAVETCH JV. Anti-inflammatory ac- cal application of subcutaneous immunoglobulin for main-
tions of intravenous immunoglobulin[J]. Annu Rev Immu- tenance treatment in CIDP：the PATH study[J]. J Peripher
nol，2008，26（1）：513-533. Nerv Syst，2018，23（4）：357-358.
[28] MADDUR MS，RABIN M，HEGDE P，et al. Intravenous [39] CIANCI P，SALVATORE S，MORETTI A，et al. Subcuta-
immunoglobulin exerts reciprocal regulation of Th1/Th17 neous immunoglobulin in infantile chronic inflammatory
cells and regulatory T cells in Guillain-Barre syndrome pa- demyelinating polyneuropathy：a case report[J]. J Pediatr
tients[J]. Immunol Res，2014，60（2/3）：320-329. Neurosci，2019，14（1）：38-41.
[29] KAUFMAN GN，MASSOUD AH，DEMBELE M，et al. [40] COCITO D，LAURIA PG，BOGGIA G，et al. Subcutane-
Induction of regulatory T cells by intravenous immuno- ous immunoglobulin IgPro20 （HIZENTRA） in patients
globulin：a bridge between adaptive and innate immunity with chronic inflammatory demyelinating polyneuropathy
[J]. Front Immunol，2015.DOI：10.3389/fimmu.2015.00469. （CIPD）in Italy：a budget impact model[J]. J Peripher
[30] OTHY S，HEGDE P，TOPCU S，et al. Intravenous gamma- Nerv Syst，2019. DOI：10.1111/jns.12312.
globulin inhibits encephalitogenic potential of pathogenic [41] AL-ZUHAIRY A，JAKOBSEN J，ANDERSEN H，et al.
T cells and interferes with their trafficking to the central Randomized trial of facilitated subcutaneous immunoglob-
nervous system，implicating sphingosine-1 phosphate re- ulin in multifocal motor neuropathy[J]. Eur J Neurol，
ceptor 1-mammalian target of rapamycin axis[J]. J Immu- 2019.DOI：10.1111/ene.13978.
nol，2013，190（9）：4535-4541. [42] NOTARANGELO LD. Primary immunodeficiencies[J]. J
[31] ANTHONY RM，KOBAYASHI T，WERMELING F，et al. Allergy Clin Immunol，2010. DOI：10.1016/j.jaci.2009.07.
Intravenous gammaglobulin suppresses inflammation 053.
through a novel T（H）2 pathway[J]. Nature，2011，475 [43] LUCAS M，LEE M，LORTAN J，et al. Infection outcomes
（7354）：110-103. in patients with common variable immunodeficiency dis-
[32] CROW AR，LAZARUS AH. Mechanistic properties of in- orders：relationship to immunoglobulin therapy over 22
travenous immunoglobulin in murine immune thrombocy- years[J]. J Allergy Clin Immunol，2010，125（6）：1354-
topenia：support for FcgammaRⅡB falls by the wayside 1360.
[J]. Semin Hematol，2016.DOI：10.1053/j.seminhematol. [44] DANIELI MG，PETTINARI L，MORETTI R，et al. Sub-
2016. 04.007. cutaneous immunoglobulin in polymyositis and dermato-
[33] SEITE JF，SHOENFELD Y，YOUINOU P，et al. What is myositis：a novel application[J]. Autoimmun Rev，2011，10
the contents of the magic draft IVIg? [J]. Autoimmun Rev， （3）：144-149.
2008，7（6）：435-439. [45] DANIELI MG，MORETTI R，GAMBINI S，et al. Open-la-
[34] SANCHEZ-RAMON S，CORBI AL，FIDALGO AG，et al. bel study on treatment with 20％ subcutaneous IgG ad-
Subcutaneous immunoglobulins：a promising alternative ministration in polymyositis and dermatomyositis[J]. Clin
for immunomodulation?[J]. Curr Pharm Des，2016，22 Rheumatol，2014，33（4）：531-536.
（41）：6300-6305. [46] CHERIN P，DELAIN JC，DE JAEGER C，et al. Subcuta-

中国药房 2020年第31卷第3期 China Pharmacy 2020 Vol. 31 No. 3 ·383 ·